Download free unlv uptown 4 life rar. Search the history of over 349 billion web pages on the Internet.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934       November 25, 2014 (Date of the earliest event reported)       Simulations Plus, Inc. (Exact name of registrant as specified in its charter)     California 001-320609 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Item 8.01     Other Events   On November 25, 2014, Simulations Plus, Inc., a California corporation (the 'Company'), held a conference call reporting its financial result for the fourth fiscal quarter and fiscal year ended August 31, 2014. The press release and the PowerPoint slides, which were used for this Conference Call, are attached herein as exhibits.

This report on Form 8-K (the 'Report'), including the disclosures set forth herein, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms 'anticipates,' 'expects,' 'estimates,' 'believes' and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements. 3 EX-99.1 2 simulations_8k-ex9901.htm PRESS RELEASE EXHIBIT 99.1 Simulations Plus Integrating Science and Software For Further Information: Simulations Plus, Inc. 42505 10 th Street West Lancaster, CA CONTACT: Simulations Plus Investor Relations Hayden IR Ms. Renee Bouche Mr.

Cameron Donahue 661-723-7723 651-653-1854 renee@simulations-plus.com cameron@haydenir.com For Immediate Release: November 25, 2014 Simulations Plus Reports FY2014 and Fourth Quarter FY2014 Financial Results Full Fiscal Year Pharmaceutical Software and Services Up 13.8%, Fourth Quarter Revenues up 27.4% LANCASTER, CA, November 25, 2014 – Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, today reported its financial results for its 2014 fiscal year (FY14) and fourth quarter (4Q14) ended August 31, 2014. On September 2, 2014, Simulations Plus acquired Cognigen Corporation, a leading provider of pharmacometric modeling and simulation services and clinical pharmacology consulting for the pharmaceutical and biotechnology industries.

Pursuant to the agreement, Cognigen has become a wholly owned subsidiary of Simulations Plus and is continuing to operate under the Cognigen name. The acquisition is expected to add approximately $5 million to the revenues of the combined company in the coming fiscal year. As a result of the acquisition, the total number of Simulations Plus employees increased from 30 to 65. In 1997, Simulations Plus entered into a royalty agreement with Therapeutic Systems Research Laboratories (TSRL), pursuant to which royalties were paid to TSRL from revenues on each license for GastroPlus basic software. On May 15, 2014, the Company entered into a buyout agreement with TSRL.

Under the terms of the Agreement, Simulations Plus will no longer pay royalties on each license of the GastroPlus software. The buyout of the prior agreement will be amortized at a constant rate of $150,000 per quarter until it is completely amortized, after which no further expense will be incurred.

For most quarters, this will result in a savings over the royalty payments that would have been made in the past. Bible weber barbecue pdf online. John DiBella, vice president for marketing and sales for Simulations Plus, said: “4Q14 was very strong for software sales, as revenue from new licenses comprised 25.5% of total revenue, and renewal rates, in terms of both accounts and revenue, exceeded 90%. Consulting service revenue saw a 7% decrease compared to 4Q13. For FY14, revenue from new licenses comprised 18.6% of total revenue, with 77 new organizations, or new departments at existing organizations, now utilizing our technology. Included among these new licenses were orders from major regulatory agencies in the US, Europe, and Asia, along with companies outside our core pharmaceutical market.